halozyme.com (HALO) - Pendapatan dodolan perusahaan

Halozyme Therapeutics, Inc. - logo grafis emiten HALO

The product realization trend for Halozyme Therapeutics (HALO) correlates with the growth of ENHANZE licensing payments and share buybacks, while 1.80 indicates the level of this metric. The business is based on innovations to convert therapies into a subcutaneous format for patient comfort. However, financial stability requires monitoring due to the potential expiration of patent protection by 2030.

Halozyme Corp (HALO): Pendapatan perusahaan saka 04.07.2022 nganti 18.11.2026

Rincian analitis perusahaan Halozyme (HALO)

Analisis umum perusahaan:HALO (halozyme.com)
Produk asli halozyme.com

Sales represent the aggregate cash flow from product realization over the reporting period. By analyzing the sales revenue of Halozyme Therapeutics (HALO), an investor assesses the business's actual market resilience to macroeconomic shocks. This metric measures actual demand, which is sensitive to the pace of post-crisis recovery. The stability of this indicator is ensured by the monopoly right of Halozyme Therapeutics (HALO) to royalties. Inelastic demand for ENHANZE technology guarantees predictable revenue growth.

Analisis perusahaan pesaing

Pendapatan perusahaan ONC|Pendapatan perusahaan Revolution Medicines, Inc. (RVMD)|Pendapatan lan volume dodolan Ascentage Pharma Group International (AAPG)|Pendapatan lan volume dodolan CGON (CG Oncology Inc)|Pendapatan dodolan perusahaan URGN|bicara.com - Pendapatan lan volume dodolan|Pendapatan dodolan perusahaan PSNL (personalis.com)|Erasca Inc (ERAS) - Pendapatan perusahaan|Dodolan perusahaan Delcath Systems|YMAB (YmAbs) - Pendapatan lan volume dodolan|AURA: Pendapatan dodolan perusahaan|Pendapatan perusahaan Candel Therapeutics, Inc. (CADL)|Pendapatan lan volume dodolan Accuray (ARAY)|Pendapatan perusahaan SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Total pendapatan perusahaan|CTOR - Pendapatan perusahaan|HURA: Pendapatan perusahaan|TARA (Protara) - Dodolan perusahaan|Fate Therapeutics, Inc. - Pendapatan dodolan perusahaan|WHWK (aadibio.com) - Pendapatan lan volume dodolan|TCRX: Pendapatan dodolan perusahaan|Pendapatan perusahaan Champions Oncology (CSBR)|XBiotech - Volume dodolan perusahaan|Pendapatan perusahaan CEL-SCI CVM|Pendapatan reged perusahaan OS Therapies (OSTX)|Radiopharm Theranostics Limited - Pendapatan lan volume dodolan|Total pendapatan perusahaan Artiva Biotherapeutics|ANL (adlainortye.com) - Dodolan perusahaan|Dodolan perusahaan Veru Pharma|TPST (Tempest Therapeutics Inc) - Pendapatan lan volume dodolan|Xilio Therapeutics, Inc. (XLO) - Pendapatan reged perusahaan|Pendapatan perusahaan Enochian BioSciences (RENB)|MURA: Pendapatan tahunan perusahaan|Pendapatan lan volume dodolan KAPA (kairospharma.com)|Pendapatan reged perusahaan OnKure (OKUR)|CytoMed Therapeutics Ltd - Pendapatan lan volume dodolan|curis.com (CRIS) - Dodolan perusahaan|Apollomics Corp (APLM) - Pendapatan perusahaan|Tharimmune - Pendapatan dodolan perusahaan|ADVB (Advanced Biomed Corp) - Pendapatan lan volume dodolan|Dodolan perusahaan Genprex, Inc (GNPX)|Pendapatan lan volume dodolan CLDI|SBFM: Pendapatan tahunan perusahaan|Pendapatan lan volume dodolan XBIO (xeneticbio.com)|Pendapatan lan volume dodolan Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Pendapatan lan volume dodolan|Total pendapatan perusahaan American Oncology Network, Inc.|BGNE: Pendapatan lan volume dodolan|Dodolan perusahaan checkpointtx.com|Pendapatan perusahaan Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Pendapatan reged perusahaan|Pendapatan perusahaan Ikena (IKNA)|NTBL - Total pendapatan perusahaan|Pendapatan perusahaan viracta.com VIRX|morphosys.com (MOR) - Total pendapatan perusahaan|NAYA Biosciences Inc - Pendapatan lan volume dodolan|AAPGV: Pendapatan perusahaan